Moreover, second-line therapies are personalized according to clinical and biochemical individual paraments as well as tumor molecular and morphology features (43, 44) to optimize the acromegaly outcome and to reduce the time of exposure to GH and IGF-I hypersecretion. The gene discussed is IGF1; the disease is neoplasm.